TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01066702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoCart
Description: implantation of an cartilagenous tissue implant derived from the patients own cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
Study: NCT00857961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: Administered Topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: Administered Topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: Administered Topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone MD-Lotion
Description: Administered Topically
Study: NCT02079298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with fluconazole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2. Treatment with both fluconazole and Ibuprofen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3. Treatment with ibuprofen.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 4. No treatment with either fluconazole nor ibuprofen.
Study: NCT02114294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated hip strengthening
Description: Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
Study: NCT02804451

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView EVO2 laryngoscope
Description: A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView EVO2 laryngoscope
Description: A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView EVO2 PCD laryngoscope
Description: A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruView EVO2 PCD laryngoscope
Description: A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView SL
Description: An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETView SL
Description: An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
Study: NCT02486419

Intervention type: OTHER
Intervention: Outdoor weather
Description: Seasonal changes in temperature

Intervention type: OTHER
Intervention: Outdoor weather
Description: Seasonal changes in temperature
Study: NCT03122847

Intervention type: DRUG
Intervention: Methylprednisolone
Description: Intravenous methylprednisolone
Study: NCT02114294

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps based training
Description: Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.

Intervention type: OTHER
Group type: OTHER
Intervention: Active control
Description: Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
Study: NCT04441749

Intervention type: DEVICE
Intervention: Images acquired by needle-based Confocal Laser Endomicroscopy (nCLE)
Description: Patients who are scheduled to undergo Robotic Navigational Bronchoscopy for a peripheral lung lesion will be enrolled. During bronchoscopy, confocal images will be captured using Cellvizio 100 Series Confocal Laser Imaging systems and their Confocal Miniprobes (Mauna Kea Technologies Paris, France). The Cellvizio system and miniprobes are FDA approved by 510(k) for use in through the respiratory tracts by endoscopy or endoscopic accessories. Only images and needle aspiration/ biopsy results from the expansion phase (20 patients) will be analyzed
Study: NCT03510221

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidants capsules
Description: 1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidants capsules
Description: 1 capsule of cranberry, 1 capsule of blueberry, and 1 capsule of pomegranate extracts were offered during 4 weeks
Study: NCT00405782

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Exercise
Description: Exercise program designed by exercise physiologist

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Exercise
Description: Exercise program designed by exercise physiologist
Study: NCT02281240

Intervention type: DRUG
Intervention: thrombopoietin, interleukin-11, heparin,
Description: The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
Study: NCT00528372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin placebo
Description: Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03484403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar back brace
Description: A brace that supports the lumbar region of the spine.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back school
Description: Back school consists of patient education physical therapy exercise instruction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back school
Description: Back school consists of patient education physical therapy exercise instruction.
Study: NCT05047614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: including sham
Description: Repositiong feedback training and biofeedback pressure training unit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: including sham
Description: Repositiong feedback training and biofeedback pressure training unit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: including sham
Description: Repositiong feedback training and biofeedback pressure training unit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: including sham
Description: Repositiong feedback training and biofeedback pressure training unit
Study: NCT01162720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long duration tourniquet
Description: Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
Study: NCT02872311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Influenza vaccine
Description: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Influenza vaccine
Description: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Influenza vaccine
Description: Licensed and FDA approved FluAd vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Influenza vaccine
Description: Licensed and FDA approved FluAd vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Influenza vaccine
Description: Licensed and FDA approved Fluvirin vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Influenza vaccine
Description: Licensed and FDA approved Fluvirin vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Influenza vaccine
Description: Licensed and FDA approved Fluvirin vaccine to be administered to study participants

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Influenza vaccine
Description: Licensed and FDA approved FluBlok vaccine to be administered to study participants
Study: NCT00156923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 190 mg
Description: Administered via IM injection once every 4 weeks for up to 3.5 years.
Study: NCT00751634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gaymar Rapr-Round (external cooling blanket)
Description: Application of the device per its approved labeling
Study: NCT01253447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: 200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02449083

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI

Intervention type: PROCEDURE
Intervention: MRI
Description: MRI

Intervention type: PROCEDURE
Intervention: coronary angiography
Description: coronary angiography

Intervention type: PROCEDURE
Intervention: coronary angiography
Description: coronary angiography

Intervention type: PROCEDURE
Intervention: coronary angiography
Description: coronary angiography
Study: NCT02283021

Intervention type: OTHER
Intervention: A biopsy sample
Description: Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.

Intervention type: OTHER
Intervention: A biopsy sample
Description: Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
Study: NCT02089438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Saxagliptin (5 mg) is given before breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin (50mg) is given before breakfast and dinner

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (100 mg) is given before breakfast
Study: NCT03770052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvie
Description: take the intervention drug once daily according to the randomized groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duvie
Description: take the intervention drug once daily according to the randomized groups
Study: NCT02878759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristbot
Description: The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
Study: NCT03324113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Pharmaceutical form: solution for eye drop~Route of administration: eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naphazoline
Description: Pharmaceutical form: solution for eye drop~Route of administration: eye drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diphenhydramine
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT04035330

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: etidronate in sodium hypochlorite
Description: using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Description: irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
Study: NCT02415283

Intervention type: DEVICE
Intervention: ¹³C-Octanoate Breath Test
Description: Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.

Intervention type: DEVICE
Intervention: ¹³C-Octanoate Breath Test
Description: Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
Study: NCT04356625

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MEPic
Description: * patient in the supine position sitting 45° to 60°,~* closed suction catheter was removed~* a 90° elbow was placed and a bacterial filter in series with endotracheal tube~* adapter was also coupled to the aneroid pressure gauge~* in series an inspiratory unidirectional valve was placed that did not allow expiration~* 2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough
Study: NCT02615678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
Study: NCT02261298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study: NCT00746109

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound packing
Description: 1/4 non-iodoform packing loosely placed inside abscess cavity.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NoPacking
Description: This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
Study: NCT01993849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine (NAC)
Description: This is the medication N-acetylcysteine (NAC)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, designed to match in appearance to NAC
Study: NCT01659671

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatopharyngoplasty
Description: Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatopharyngoplasty
Description: Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
Study: NCT04560062

Intervention type: OTHER
Intervention: Spontaneous changes in diabetes-related health care
Description: The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.

Intervention type: OTHER
Intervention: Spontaneous changes in diabetes-related health care
Description: The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
Study: NCT00945399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CARTIPATCH® procedure
Description: Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
Study: NCT02447718

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®13
Description: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax® 23
Description: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel®
Description: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
Study: NCT02100683

Intervention type: DEVICE
Intervention: PDA Coil
Description: The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
Study: NCT02830828

Intervention type: OTHER
Intervention: Investigation of precision pinch grip control

Intervention type: OTHER
Intervention: Investigation of precision pinch grip control
Study: NCT01711346

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: S303 Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S303 Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, untreated Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional, untreated Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
Study: NCT01792843

Intervention type: BEHAVIORAL
Intervention: data
Description: * comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features
Study: NCT00749359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxil CR
Description: Paxil CR 37mg tablet manufactures at two different sites
Study: NCT04040998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training
Description: Teach the participants compensatory cognitive skills and strategies